Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

As Donald J. Trump gradually fills out his cabinet, the President-elect’s latest pick could bode well for biopharma business ...

Oppenheimer analyst Jay Olson maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $380.00. The company’s ...

TheAmgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to ...

Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found that a DNA sequencing test for advanced prostate cancer patients can ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

The board of Amgen boosted its quarter dividend by almost 6%. The Thousand Oaks, Calif.-based biotechnology company said Tuesday that it raised its dividend to $2.38 per share for the first quarter, ...

Amgen (NASDAQ:AMGN) declares $2.38/share quarterly dividend, 5.8% increase from prior dividend of $2.25. Forward yield 3.45% ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate ...

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the ...

Latest update on the Dow Jones Industrial Average (DJIA), which recently closed at 44,401.93. Discover market trends, top-performing stocks..